In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Vigorous physical activity may preserve cognitive function in high-risk HTN
Jun 24, 2024
High versus low vigorous physical activity was linked to a lower risk of mild cognitive impairment, probable dementia and MCI/probable dementia in a multivariate model.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Dementia with Lewy bodies risk down with α-1 adrenergic receptor antagonists
Jun 19, 2024
The risk for developing dementia with Lewy bodies was lower for men newly started on Tz/Dz/Az compared with those taking tamsulosin or 5ARI.
Nearly one in four do not recover from COVID-19 by 90 days
Jun 19, 2024
Female sex and preexisting cardiovascular disease were tied to longer recovery times.
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
Residual risk seen for death, postacute sequelae in third year after COVID-19 hospitalization
Jun 13, 2024
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
Tau PET performs well in predicting dementia in individuals with MCI
Jun 12, 2024
Tau positron emission tomography predicts all-cause dementia and Alzheimer disease dementia
Systemic side effects of COVID-19 vaccine tied to greater nAB response
Jun 11, 2024
Each 1-degree Celsius increase in skin temperature after a dose was linked to a 1.8- and 3.1-fold higher neutralizing antibody response one and six months later.
Nirmatrelvir-ritonavir no aid for long COVID symptoms
Jun 10, 2024
The findings based on symptoms at 10 weeks following 15-day course in vaccinated cohort.